

# Rapid, high titer expression of antibody derivatives using *Pseudomonas fluorescens*


Cory Schwartz\*, Russell Coleman, Yinghui Lee, Scott McVicar, Jason Payne, Hongfan Jin, Torben Bruck, Jeff Allen, and Diane Retallack

## Abstract

While antibodies and their derivatives remain critical scaffolds for novel therapeutic development, scaling production in common hosts like *E. coli* is often difficult due to their structure and complex disulfide bonding. A *Pseudomonas fluorescens* expression platform has been developed that overcomes these challenges and enables rapid, high quality expression of therapeutic antibody derivatives. The Pfenex platform leverages a varied toolbox of expression plasmids and a wide array of different production hosts to quickly identify high producing strains. Using automation-enabled high throughput screening workflows, a production strain can be identified and scaled to a fermentation process in as few as 12 weeks. This platform screening process has successfully been used to produce high levels of a range of antibody derivatives, including a trimeric multifunctional antibody derivative, peptidobodies, Fabs, and scFvs.

## Methods


### Pfenex Toolbox



Toolbox components are combined to produce thousands of unique expression strains to be screened in parallel


## Rapid Cloning Process

Digest and ligate synthesized DNA fragment in single reaction with expression plasmid, and transform directly




- Gene fragments synthesized; no PCR amplification or sequencing of target required
- Rapid cloning requires use of a single restriction enzyme
- Clone in-frame with different combinations of RBS strengths and periplasmic secretion leaders incorporated into single and dual operon expression plasmids
- Plasmids maintained by *pyrF* complementation

## Methods Automated, High-throughput Strain Screening and Analysis



## Case Studies


### Protein-Fc fusion - Soluble Expression



Optimal strain produced more than 2 g/L of soluble assembled protein-Fc fusion

### Trimeric Multifunctional Antibody Derivative Expression


Screening of 270 expression strategies in high-throughput and functional binding assay to determine high producing strains



Soluble active expression of more than 1 g/L achieved without fermentation optimization

### FAB Expression and Optimization

Screen variable heavy and light chain expression ratios



Strain screening and fermentation scale-up resulted in over 4 g/L assembled (CGE and MS) and active (BLI) FAB produced

## Summary

- Extensive expression toolbox: expression strategies and host strains
- Robust high throughput methods developed to identify best strains quickly to produce active proteins at high titers
- A wide variety of antibody derivatives can be produced using the platform